Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT06667076) titled 'A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)' on Oct. 30, 2024.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Carcinoma, Non-Small-Cell Lung
Intervention:
Drug: Amivantamab
Drug: Lazertinib
Drug: Chemotherapy: Pemetrexed
Recruitment St...